Document text
Principal Investigator: MARLENE BOUVIER
Organization: UNIVERSITY OF ILLINOIS AT CHICAGO
Fiscal Year: 2024
Award: $199,875
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current pandemic
of coronavirus-induced disease 2019 (COVID-19). Since December 2019, coordinated research efforts have
provided a wealth of critical data that have enhanced our ability to diagnose and treat COVID-19. To date,
however, much of the molecular and cellular mechanisms underlying the pathogenesis of COVID-19 remain
elusive. The genome of SARS-CoV-2 contains nine independent open reading frames (ORFs) coding for
proteins that are not essential for viral replication but seem to exert important functions in modulating host
antiviral immunity. Of these accessory proteins, the ORF8 protein stands out for its unique characteristics.
ORF8 is a highly variable protein among SARS-related CoVs. ORF8 also appears to be involved in a network
of host-pathogen interactions inside infected cells: ORF8 impairs immune pathways such as antigen
presentation, interferon type I, and nuclear factor-kB, as well as possibly activate growth pathways. A central
question is how ORF8 mediates interactions with multiple host protein targets. Towards this goal, we are
investigating ORF8 interaction with major histocompatibility class I (MHC I) molecules.
It was shown recently that SARS-CoV-2 ORF8 suppresses CD8+ T cell responses by downregulating MHC
I molecules, both in vitro and in vivo. We hypothesize that ORF8 suppresses surface expression of HLA-A and
HLA-B molecules to protect infected cells from recognition by CD8+ T cells, but spares HLA-C and HLA-E to
avoid activation of natural killer (NK) cells. The possibility that ORF8 displays a locus specificity toward MHC I
would provide a mechanism for SARS-CoV-2 to walk a fine line between adaptive and innate immunity.
Specifically, we will undertake an analysis of interactions between ORF8 and MHC I by using a panel of HLA-
A, -B, -C, and -E molecules, and also determine if ORF8 selectively downregulates MHC I in relevant cell
systems (Aim 1). We will extend these studies to ORF8 variants that have been positively selected during the
course of the pandemic and evaluate if and how these mutations affect MHC I binding and downregulation
(Aim 2). The successful completion of these Aims is expected to uncover unknown features of ORF8 and
elucidate its role in suppressing antigen presentation, as well as inform us on the selective pressure that MHC I
exerts on SARS-CoV-2. The immediate and long-term impact of our proposed research is high. This is the first
study that: (1) characterizes molecular interaction of ORF8 with a host protein; and (2) evaluates clinically
relevant ORF8 variants. By studying the immune interactions underlying ORF8-mediated downregulation of
MHC I, we will increase our understanding of how SARS-CoV-2 derails cellular immunity. Importantly, our
study will stimulate similar investigations of other ORF8-interactors, providing novel opportunities for the
development of therapeutics directed against ORF8 or its host targets.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Affect><Alleles><Allelomorphs><Antigen Presentation><Antigenic Determinants><Assay><Binding><Binding Determinants><Bioassay><Biological Assay><Biology><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19><COVID-19 genome><COVID-19 infection><COVID-19 pathogenesis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 virus genome><COVID-19 virus infection><COVID19 genome><COVID19 infection><COVID19 pathogenesis><COVID19 virus><COVID19 virus genome><CV-19><Cell Body><Cell Mediated Immunology><Cell surface><Cell-Mediated Immunity><Cells><Cellular Immune Function><Cellular Immunity><Characteristics><Class I Antigens><Class I Major Histocompatibility Antigens><CoV-2><CoV2><Code><Coding System><Complex><Complex Class 1><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Crystallization><Cytotoxic cell><Data><Development><Diagnosis><Disease><Disorder><Down-Regulation><Endowment><Epitopes><Evaluation><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Future><Generalized Growth><Genetic Alteration><Genetic Change><Genetic defect><Genomic Segment><Goals><Growth><HLA-A><HLA-A gene><HLA-B><HLA-B Antigens><HLA-C><HLA-C Antigens><HLAA><Histocompatibility><Histocompatibility Antigens Class I><Immune><Immune Evasion><Immunes><Impairment><In Vitro><Innate Immune Response><Innate Immunity><Interferon Type I><Investigation><K lymphocyte><Knowledge><MHC Class I Molecule><MHC Class I Protein><MHC class I antigen><Major Histocompatibility Complex Class 1><Mediating><Molecular><Molecular Interaction><Morbidity><Morbidity - disease rate><Mutation><NK Cell Activation><NK Cells><Native Immunity><Natural Immunity><Natural Killer Cell Activation><Natural Killer Cells><Non-Specific Immunity><Nonspecific Immunity><Nuclear><ORFs><Open Reading Frames><Pathogenesis><Pathologic><Pathway interactions><Patients><Phenotype><Protein Coding Region><Proteins><Research><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 genome><SARS-CoV-2 infection><SARS-CoV-2 pathogenesis><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 genome><SARS-CoV2 infection><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scheme><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Specificity><Structure><Surface><System><T cell response><T8 Cells><T8 Lymphocytes><Tissue Compatibility><Tissue Growth><Variant><Variation><Viral><Virulence><Virus><Virus Replication><Wuhan coronavirus><adaptive immune response><adaptive immunity><anti-viral immunity><antiviral immunity><cell transduction><cellular transduction><clinical relevance><clinically relevant><corona virus><coronavirus disease 2019><coronavirus disease 2019 genome><coronavirus disease 2019 infection><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease 2019 virus genome><coronavirus disease-19><coronavirus disease-19 pathogenesis><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus of pandemic concern><coronavirus of pandemic potential><coronavirus with pandemic potential><current pandemic><developmental><exhaustion><experience><flow cytophotometry><gel electrophoresis><genome mutation><genome segment><genomic region><hCoV19><human pathogen><immune evasive><immune function><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><interest><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mortality><mutant><nCoV2><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ontogeny><pandemic><pandemic coronavirus><pandemic disease><pandemic threat coronavirus><pathogen><pathway><present pandemic><pressure><prevent><preventing><protein protein interaction><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 genome><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><small molecular inhibitor><small molecule inhibitor><social role><therapeutic agent development><therapeutic development><transduced cells><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral multiplication><viral replication><virus multiplication>